Healthy
Conditions
Brief summary
The purpose of this study is to evaluate the pharmacokinetic study of the combination of digoxin and polythylene glycol loxenatide injection (PEX168) in healthy adults，and to provide scientific basis for clinical combination of PEX168 and drugs.This study is also to evaluate the safety and tolerability of mono-digoxin or digoxin plus PEX168.
Detailed description
This will be an open-label, single-arm, sequential, single-center clinical trial. 16 healthy males will be admitted to the clinical facility on Day -1, the day prior to the start of dosing. The subjects will be observed in clinic twice: Day -1 to 8 and Day 37 to 44. Subjects will receive a single dose of digoxin on Day 1 followed by 5 weekly subcutaneously injected doses of PEX168 and a second single dose of digoxin on Day 38. To determine the pharmacokinetic parameters of digoxin after drug administration alone and after multiple doses of PEX168, blood and urine samples will be collected after each dose of digoxin and tested by the laboratory.The subjects will be discharged on Day 8 and Day 44. Approximately 28 days after the last discharge, the subjects will be called for a post study visit.
Interventions
DRUGDigoxin
Digoxin 0.5mg tablet by mouth on Day 1 and Day 38
DRUGPEX168
PEX168 in subcutaneous injection on Day8，15，22，29 and Day 36
Sponsors
First Affiliated Hospital Xi'an Jiaotong University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy males aged from 18 to 45 years 2. Have a body weight over 50kg, have a body mass index (BMI) 19-25 kg/m\^2 (both inclusive) 3. Alanine aminotransferase\<50 U/L, aspartate aminotransferase\<50 U/L, alkaline phosphatase and total bilirubin \<1.5x the upper limit of normal 4. According to Cockcroft-Gault, estimated Clcr≥90ml/min 5. Able to comprehend and willing to sign the informed consent form
Exclusion criteria
1. Hepatitis B surface antigen(+)， Hepatitis C virus antibody(+)，AIDS antibody（+） 2. History of syncope, palpitations, bradycardia and tachycardia (for example any degree of atrioventricular block, left bundle branch block, right bundle branch block), or have an abnormal result of overall physical examination (vital signs, physical examination), routine laboratory assessment (hematology, biochemistry and urinalysis), 12-lead ECG and abdominal sonography (liver, gallbladder, pancreas, spleen, kidney) 3. Have had an alcohol and substance abuse within 6 months of screening 4. History of smoking within 3 months of screening 5. BP\>140/90 millimetres of mercury, or heart rate \>100 bpm 6. QT interval \>450ms 7. History of drug-induced allergy or of hypersensitivity for digoxin and PEX168 8. History of serious heart disease or lung disease 9. Fasting triglyceride\>1.5x the upper limit of normal 10. Subjects with liver disease or have history of liver disease or abnormal liver and gallbladder conditions 11. Donation of blood in excess of 400 mL within the 3 months of screening; or donation of blood within 1 month of screening; or received blood transfusions within 1 month of screening. 12. Hypothyroidism 13. Surgery of gastrointestinal tract 14. History of pancreatitis 15. History of cholecystitis or other gallbladder disease 16. History of inflammatory bowel disease or irritable bowel syndrome 17. History of MEN type 2 syndrome 18. History of medullary thyroid carcinoma 19. A family history of MEN type 2 syndrome and medullary thyroid carcinoma 20. Have participated in clinical trials with drug or medical devices involved within 3 months of screening 21. Have received any drug that may affect the study drugs within 2 weeks of screening, including prescribed drugs, over-counted drugs, Chinese traditional medicine or multivitamins 22. History of grapefruit juice, cranberry, mango, foods and drinks of xanthine or caffeine, strenuous exercise, or any other factor affect the absorption, distribution, metabolism and excretion of the study drug within 2 days of screening 23. Have received any glucagon-like peptide-1 mimetic compound(e.g., exenatide) 24. Have been disagreed to use a reliable method of birth control during the study and for 6 months following the last dose of study drug 25. History of any other condition, which in the opinion of the investigator, may prevent the subject from following and completing the protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Composite of pharmacokinetic (PK) parameters of digoxin with and without PEX168 in plasma and urine (cmax, t 1/2) | Day 1 through Day 44 | Maximum observed concentration in plasma(cmax); apparent terminal elimination half-life in plasma(t1/2). |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants with Adverse Events as a Measure of Safety and Tolerability | Day 1 through Day 44 |
Countries
China
Outcome results
None listed